Table 2.
Primary and Secondary Outcomes
| Outcome | Daptomycin Plus Fosfomycin, No. of Patients/Total (%) | Daptomycin Alone, No. of Patients/Total (%) | Relative Risk (95% CI) |
|---|---|---|---|
| Primary endpoint | |||
| Treatment success at TOC | 40/74 (54.1) | 34/81 (42.0) | 1.29 (.93–1.8) |
| Secondary endpoints | |||
| Positive blood cultures at day 3 | 2/74 (2.7) | 15/81 (18.5) | 0.15 (.04–.63) |
| Positive blood cultures at day 7 | 0/74 (0.0) | 5/81 (6.2) | −6.2 (−11.4 to −.9)a |
| Positive blood cultures at TOC | 0/74 (0.0) | 4/81 (4.9) | −4.9 (−9.7 to −.2)a |
| Microbiological failure at TOC | 0/74 (0.0) | 9/81 (11.1) | −11.1 (−18.0 to –4.3)a |
| No. of episodes of complicated bacteremia at TOC | 12/74 (16.2) | 26/81 (32.1) | 0.51 (.28–.94) |
| Any AE leading to treatment discontinuation | 13/74 (17.6) | 4/81 (4.9) | 3.56 (1.21–10.44) |
| Overall mortality at day 7 | 3/74 (4.1) | 6/81 (7.4) | 0.55 (.14–2.12) |
| Overall mortality at TOC | 18/74 (24.3) | 22/81 (27.2) | 0.9 (.53–1.54) |
Abbreviations: AE, adverse event; CI, confidence interval; TOC, test of cure.
aProportion difference, as it was not possible to estimate the relative risk.